|
Review
The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
Sung-Yong Kim, Sung Hwa Bae, Soo-Mee Bang, Ki-Seong Eom, Junshik Hong, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Min Kyoung Kim, Soo-Jeong Kim, Yeung-Chul Mun, Seung-Hyun Nam, Jinny Park, Jong-Ho Won, Chul Won Choi
Korean J Intern Med. 2021;36(1):45-62. Published online December 4, 2020
In 2016, the World Health Organization revised the diagnostic criteria for myeloproliferative neoplasms (MPNs) based on the discovery of disease-driving genetic aberrations and extensive analysis of the clinical characteristics of patients with MPNs. Recent studies have suggested that additional som..
|
|
|
Hemato-oncology / Original Article
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer
Min Young Baek, Hee Kyung Ahn, Kyu Ree Park, Hwa-Sun Park, Shin Myung Kang, Inkeun Park, Young Saing Kim, Junshik Hong, Sun Jin Sym, Jinny Park, Jae Hoon Lee, Dong Bok Shin, Eun Kyung Cho
Korean J Intern Med. 2018;33(1):168-175. Published online April 20, 2016
Background/Aims: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis, considering the epidermal growth factor receptor (EGFR) mutational status...
|
|
|
Hemato-oncology / Review
Guidelines for the management of myeloproliferative neoplasms
Chul Won Choi, Soo-Mee Bang, Seongsoo Jang, Chul Won Jung, Hee-Jin Kim, Ho Young Kim, Soo-Jeong Kim, Yeo-Kyeoung Kim, Jinny Park, Jong-Ho Won
Korean J Intern Med. 2015;30(6):771-788. Published online October 30, 2015
Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as ‘Philadelphia-negative classical myeloproliferative neoplasms (MPNs).’ The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysio..
|
|
|
|
|
Original Article
Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
Junshik Hong, Sun Young Kyung, Sang Pyo Lee, Jeong Woong Park, Sung Hwan Jung, Jae-Ik Lee, Se Hoon Park, Sun Jin Sym, Jinny Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
Korean J Intern Med. 2010;25(3):294-300. Published online August 31, 2010
Background/AimsThe efficacy and safety of pemetrexed, gefitinib, and erlotinib administration in previously treated patients with non-small cell lung cancer (NSCLC) were compared. MethodsThe study patients met the following criteria: histologica..
|
|
|
